The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones
Open accessAbstract
The quinone pharmacophore is present in many drug classes but is particularly common among antitumor drugs. Many quinones serve essentially as pro-drugs and exert their activities after reduction. Reduction of quinones may generate semiquinones or hydroquinones with subsequent generation of reactive oxygen radicals and oxidative stress, quinones can be designed so they lose a leaving group when reduced to the hydroquinone generating a reactive electrophile or the hydroquinone form of the molecule may have greater pharmacological activity than the parent quinone against a particular target. Enzyme systems that reduce quinones therefore become critically important in the pharmacological activity of this class of drugs. There are a number of enzyme systems that can catalyze reduction of quinones including cytochrome P450 reductase, cytochrome b5 reductase, NAD(P)H:quinone oxidoreductase 1 (NQO1), NAD(P)H:quinone oxidoreductase 2 (NQO2), carbonyl reductases, and thioredoxin reductase. In this context, one of the most extensively studied reductases has been NAD(P)H:quinone oxidoreductase 1 (NQO1). In this review we will focus on the role of NQO1 in the bioactivation of clinically important quinones mitomycin C, β-lapachone and 17AAG as well as the influence of the NQO1*2 polymorphism on the sensitivity and resistance to these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
GELDANAMYCIN, A NEW ANTIBIOTIC
DEBOER, C., MEULMAN, P. A., WNUK, R. J., & PETERSON, D. H. (1970) · The Journal of Antibiotics · doi:10.7164/antibiotics.23.442 · Cited by 466
NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity
Pink, J. J., Planchon, S. M., Tagliarino, C., Varnes, M. E., Siegel, D., & Boothman, D. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5416 · Cited by 376
Self-citationBey, E. A., Bentle, M. S., Reinicke, K. E., Dong, Y., Yang, C.-R., Girard, L., Minna, J. D., Bornmann, W. G., Gao, J., & Boothman, D. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702176104 · Cited by 354
Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 350
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
[30] DT-diaphorase: Purification, properties, and function
Lind, C., Cadenas, E., Hochstein, P., & Ernster, L. (1990) · Methods in Enzymology · doi:10.1016/0076-6879(90)86122-c · Cited by 321
Traver, R. D., Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Danenberg, P. V., Ross, D., & Gibson, N. W. (1992) · PubMed · Cited by 313
Self-citationImmunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues
Siegel, D., & Ross, D. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00310-5 · Cited by 298
Self-citationBasso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Schlager, J. J., & Powis, G. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450304 · Cited by 262
NAD(P)H:Quinone Oxidoreductase 1 (NQO1, DT-Diaphorase), Functions and Pharmacogenetics
Ross, D., & Siegel, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)82008-1 · Cited by 245
Self-citationNimmanapalli, R., O’Bryan, E., & Bhalla, K. N. (2001) · PubMed · Cited by 242
Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H: quinone oxidoreductase 1
Siegel, D., McGuinness, S. M., Winski, S. L., & Ross, D. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00015 · Cited by 239
Self-citationUehara, Y., Hori, M., Takeuchi, T., & Umezawa, H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.6.2198 · Cited by 233
Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R., & Lewis, A. D. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.5.259 · Cited by 232
Siegel, D. M., Nw, G., Preusch, P. C., & Ross, D. (1990) · PubMed · Cited by 222
Self-citationLi, C. J., Averboukh, L., & Pardee, A. B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41552-9 · Cited by 219
Fagerholm, R., Hofstetter, B., Tommiska, J., Aaltonen, K., Vrtel, R., Syrjäkoski, K., Kallioniemi, A., Kilpivaara, O., Mannermaa, A., Kosma, V.-M., et al. (2008) · Nature Genetics · doi:10.1038/ng.155 · Cited by 208
Siegel, D., Anwar, A., Winski, S. L., Kepa, J. K., Zolman, K. L., & Ross, D. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12836-2 · Cited by 207
Self-citationCresteil, T., & Jaiswal, A. K. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90284-c · Cited by 201
Faig, M., Bianchet, M. A., Talalay, P., Chen, S., Winski, S., Ross, D., & Amzel, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3177 · Cited by 192
Self-citationKelsey, K., Ross, D., Traver, R., Christiani, D., Zuo, Z.-F., Spitz, M., Wang, M., Xu, X., Lee, B.-K., Schwartz, B., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.474 · Cited by 187
Self-citationMünster, P. N., Marchion, D. C., Basso, A. D., & Rosen, N. X. (2002) · PubMed · Cited by 182
Update of the NAD(P)H:Quinone oxidoreductase (NQO) gene family
Vasiliou, V., Ross, D., & Nebert, D. W. (2006) · Human Genomics · doi:10.1186/1479-7364-2-5-329 · Cited by 178
Self-citationRole of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
Keyes, S. R., Fracasso, P. M., Heimbrook, D. C., Rockwell, S., Sligar, S. G., & Sartorelli, A. C. (1984) · PubMed · Cited by 176
Guo, W., Reigan, P., Siegel, D., Zirrolli, J., Gustafson, D., & Ross, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2029 · Cited by 176
Self-citationOugh, M., Lewis, A., Bey, E. A., Gao, J., Ritchie, J. M., Bornmann, W., Boothman, D. A., Oberley, L. W., & Cullen, J. J. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.1.1382 · Cited by 173
Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
Siegel, D. M., Franklin, W. A., & Ross, D. (1998) · PubMed · Cited by 164
Self-citationBoothman, D. A., Trask, D. K., & Pardee, A. B. (1989) · PubMed · Cited by 164
Bioreductive activation of mitomycin C by DT-diaphorase
Siegel, D. M., Beall, H. D., Senekowitsch, C., Kasai, M., Arai, H., Gibson, N. W., & Ross, D. (1992) · Biochemistry · doi:10.1021/bi00149a019 · Cited by 156
Self-citationFumo, G., Akin, C., Metcalfe, D. D., & Neckers, L. (2003) · Blood · doi:10.1182/blood-2003-07-2477 · Cited by 149
Calcium Is a Key Signaling Molecule in β-Lapachone-mediated Cell Death
Tagliarino, C., Pink, J. J., Dubyak, G., Nieminen, A., & Boothman, D. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100730200 · Cited by 147
Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells.
Boothman, D. A., Meyers, M., Fukunaga, N., & Lee, S. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.15.7200 · Cited by 134
Gaspar, N., Sharp, S. Y., Pacey, S., Jones, C., Walton, M. I., Vassal, G., Eccles, S. A., Pearson, A. D. J., & Workman, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3131 · Cited by 124
β-Lapachone-Induced Apoptosis in Human Prostate Cancer Cells: Involvement of NQO1/xip3
Planchon, S. M., Pink, J. J., Tagliarino, C., Bornmann, W. G., Varnes, M. E., & Boothman, D. A. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5234 · Cited by 118
Bagatell, R., Khan, O., Paine-Murrieta, G. D., Taylor, C. W., Akinaga, S., & Whitesell, L. J. (2001) · PubMed · Cited by 118
Li, L. S., Bey, E. A., Dong, Y., Meng, J., Patra, B., Yan, J., Xie, X., Brekken, R. A., Barnett, C. C., Bornmann, W. G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1983 · Cited by 115
Effect of β-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi
BOVERIS, A., Docampo, R., Turrens, J. F., & Stoppani, A. O. M. (1978) · Biochemical Journal · doi:10.1042/bj1750431 · Cited by 112
Structure and Mechanism of NAD[P]H:Quinone Acceptor Oxidoreductases (NQO)
Bianchet, M. A., Faig, M., & Amzel, L. M. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82009-3 · Cited by 112
Winski, S. L., Hargreaves, R. H. J., Butler, J. A. V., & Ross, D. (1998) · PubMed · Cited by 109
Self-citationSubcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.
Winski, S. L., Koutalos, Y., Bentley, D. L., & Ross, D. (2002) · PubMed · Cited by 107
Self-citationGaedigk, A., Tyndale, R. F., Jurima‐Romet, M., Sellers, E. M., Grant, D. M., & Leeder, J. S. (1998) · Pharmacogenetics · doi:10.1097/00008571-199808000-00004 · Cited by 102
NQO1 Expression in Pancreatic Cancer and Its Potential Use as a Biomarker
Awadallah, N. S., Dehn, D. L., Shah, R. J., Nash, S. R., Chen, Y. K., Ross, D., Bentz, J. S., & Shroyer, K. R. (2008) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31802e91d0 · Cited by 80
Self-citationpH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells.
Kennedy, K. A., McGurl, J. D., Leondaridis, L., & Alabaster, O. (1985) · PubMed · Cited by 76
Docampo, R., Cruz, F. S., Boveris, A., Muniz, R. P. A., & Esquivel, D. M. S. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90348-4 · Cited by 76
Su, P., Forrest, G. L., Akman, S. A., & Hu, L. T. (1995) · PubMed · Cited by 75
Choi, E. K., Terai, K., Ji, I.-M., Kook, Y. H., Park, K. H., Oh, E. T., Griffin, R. J., Lim, B. U., Kim, J., Lee, D. S., et al. (2007) · Neoplasia · doi:10.1593/neo.07397 · Cited by 73
Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
Keyes, S. R., Rockwell, S., & Sartorelli, A. C. (1985) · PubMed · Cited by 70
Strassburg, A., Strassburg, C. P., Manns, M. P., & Tukey, R. H. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.2.320 · Cited by 67
Guo, W., Reigan, P., Siegel, D. M., & Ross, D. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022004 · Cited by 66
Self-citationTsvetkov, P., Adamovich, Y., Elliott, E., & Shaul, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193276 · Cited by 63
Chen, S., Wu, K., Zhang, D., Sherman, M. A., Knox, R. J., & Yang, C. S. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.2.272 · Cited by 61
Guo, W., Reigan, P., Siegel, D. M., Zirrolli, J. A., Gustafson, D. L., & Ross, D. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025643 · Cited by 60
Self-citationChemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C
Keyes, S. R., Heimbrook, D. C., Fracasso, P. M., et al. (1985) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(85)90053-6 · Cited by 52
Synergistic Effects of Radiation and β-Lapachone in DU-145 Human Prostate Cancer Cells In Vitro
Suzuki, M., Amano, M., Choi, J., Park, H. J., Williams, B. W., Ono, K., & Song, C. W. (2006) · Radiation Research · doi:10.1667/rr3554.1 · Cited by 50
β-Lapachone greatly enhances MMS lethality to human fibroblasts
Boorstein, R. J., & Pardee, A. B. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91469-4 · Cited by 42
Park, H. J., Choi, E. K., Choi, J., Ahn, K.-J., Kim, E. J., Ji, I.-M., Kook, Y. H., Ahn, S.-D., Williams, B. W., Griffin, R. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0818 · Cited by 38
Cowen, R. L., Patterson, A. V., Telfer, B. A., Airley, R. E., Hobbs, S., Phillips, R. M., Jaffar, M., Stratford, I. J., & Williams, K. J. (2003) · PubMed · Cited by 37
Hu, L. T., Stamberg, J., & Pan, S. (1996) · PubMed · Cited by 35
The activity of the D-T diaphorase in experimental hepatomas.
Schor, N. A., & Morris, H. P. (1977) · PubMed · Cited by 35
Begleiter, A., Leith, M. K., Thliveris, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602171 · Cited by 34
Yu, W., Rao, Q., Wang, M., Tian, Z., Lin, D., Liu, X., & Wang, J. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.08.028 · Cited by 34
Jamieson, D., Cresti, N., Bray, J., Sludden, J., Griffin, M. J., Hawsawi, N. M., Famie, E., Mould, E. V. A., Verrill, M. W., May, F. E. B., et al. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834b6918 · Cited by 33
Characterization of a human bladder cancer cell line selected for resistance to mitomycin C
Xu, B., Gupta, V. D., & Singh, S. V. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580512 · Cited by 31
Dong, G.-Z., Youn, H., Park, M., Oh, E., Park, K. H., Song, C. W., Choi, E. K., & Park, H. J. (2009) · International Journal of Hyperthermia · doi:10.1080/02656730903049836 · Cited by 29
Zajac, M., Goméz-López, G., Benitez, J. J., & Martínez–Delgado, B. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-44 · Cited by 29
Basu, S., Brown, J. E., Flannigan, G. M., Gill, J. H., Loadman, P. M., Martin, S. W., Naylor, B., Scally, A., Seargent, J. M., Shah, T. K., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20005 · Cited by 27
Boorstein, R. J., & Pardee, A. B. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)91536-x · Cited by 27
Yamaki, H., Suzuki, H., Choi, E. C., & Tanaka, N. (1982) · The Journal of Antibiotics · doi:10.7164/antibiotics.35.886 · Cited by 27
Anti-cancer effect of bio-reductive drug β-lapachon is enhanced by activating NQO1 with heat shock
Song, C. W., Chae, J. J., Choi, E. K., Hwang, T. S., Kim, C., Lim, B. U., & Park, H. J. (2008) · International Journal of Hyperthermia · doi:10.1080/02656730701781895 · Cited by 19
Adikesavan, A. K., Barrios, R. J., & Jaiswal, A. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4480 · Cited by 16
Reigan, P., Siegel, D. M., Guo, W., & Ross, D. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070086 · Cited by 15
Self-citationDouglas, M., Lim, A. R., Porter, J. R., West, K. A., Pink, M. M., Ge, J., Wylie, A. A., Tibbits, T. T., Biggs, K., Curtis, M. S., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0568 · Cited by 15
Biochemical characterization of a mitomycin C resistant colon cancer cell line variant
Perry, R. R., Kang, Y., & Greaves, B. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90642-a · Cited by 13
Shibata, K., Kasahara, K., Bando, T., Nakatsumi, Y., Fujimura, M., TSURUO, T., & Matsuda, T. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03079.x · Cited by 11
Cited by
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
Hu, C., Yang, J., Qi, Z., Wu, H., Wang, B., Zou, F., Mei, H., Liu, J., Wang, W., & Liu, Q. (2022) · MedComm · doi:10.1002/mco2.161 · Cited by 779
The diverse functionality of NQO1 and its roles in redox control
Ross, D., & Siegel, D. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101950 · Cited by 499
Self-citationNrf2 at the heart of oxidative stress and cardiac protection
Chen, Q. M., & Maltagliati, A. J. (2018) · Physiological Genomics · doi:10.1152/physiolgenomics.00041.2017 · Cited by 474
Zhao, Y., Hu, Q., Cheng, F., Su, N., Wang, A., Zou, Y., Hu, H., Chen, X., Zhou, H.-M., Huang, X., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.009 · Cited by 433
Metadata
- Authors
- Siegel, D., Yan, C., & Ross, D.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 83
- Issue
- 8
- Pages
- 1033-1040
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2064245899
- Cited by
- 272
- References
- 79
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.